💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Solara Active Pharma Sciences Limited is an India-based global, pureplay active pharmaceutical ingredients (API) company. The Company is engaged in the manufacturing and development of APIs and offers contract manufacturing and development services for global companies. Its…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A weak business — but flagged on governance.
Solara Active Pharma Sci is scored on the pharma / healthcare framework. It keeps a thin -0.5% of every rupee of sales as net profit. Free cash flow is worth about 1.8% of its market value.
Net worth has actually shrunk (-6%/yr) — value is not being built. Return on equity is a weak 3.3%. In the latest quarter profit grew 74% versus the prior quarter.
It trades at 83× earnings. Today's price already implies ~29%/yr earnings growth sustained for a decade — a demanding bar. The forensic screen raises a red flag: Share count up 22% over 4 years — heavy equity dilution.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 83.39 | — | — |
| P/B | 2.14 | 4.11 | better |
| EV/EBITDA | 15.75 | 19.15 | better |
| ROE | 3.3 | 0.68 | better |
| ROCE | 6.75 | 6.87 | worse |
| ROA | 1.51 | 1.26 | better |
| Quick Ratio | 0.6 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Negative CAGR — the top line has shrunk over this window. Growth is accelerating — latest year outpaced the prior year's rate.
3 of the 4 years shown had a loss — profitability is inconsistent. The latest year saw a -1472% swing — check if it's a one-off or structural.
Operating margin has expanded from -3% to -1% — the business is keeping more of each rupee earned.
Negative ROE — the business is destroying shareholder value.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 9% sequentially — momentum is building. Run-rate stepping up — recent quarters average 8% above earlier ones.
1 of 4 quarters loss-making — quarterly profitability is uneven. Profit jumped 74% QoQ — check if this is operating leverage or a one-off item. Quarterly net margins are expanding (-5% → 7%) — profitability per rupee of revenue is improving.
P/E band unavailable — needs 5y of consistent EPS + price history.
Promoters at 41.9% — dispersed ownership; institutional flows drive the stock.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.